Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia

Atherosclerosis

Volumn 129, Issue 2, 1997, Pages 241-248

  Homma, Yasuhiko ^a   Kobayashi, Toshio ^a   Yamaguchi, Hiroshi ^a   Ozawa, Hideki ^a   Sakane, Hiroya ^a   Nakamura, Haruo ^b  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

bile acid sequestrant; CETP; hyperlipoproteinemia; LCAT; LDL receptor; lipoprotein subfraction

Indexed keywords

COLESTILAN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; RESIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; BILE ACIDS AND SALTS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; GLYCOPROTEINS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; MOLECULAR WEIGHT; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 0030897423     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06034-0     Document Type: Article

References (36)

1. Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995;1841.
2. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995;1981.
3. Crouse JR, Parks JS, Schey HM, Kahl FR. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985;26:566.
4. Austin MA, Breslow JL, Hennekens CH, Burning JE, Willet WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917.
5. Campos H, Genest JJ, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187.
6. Homma Y, Moriguchi EH, Sakane H, Ozawa H, Nakamura H, Goto Y. Effects of probucol on plasma lipoprotein subfractions and activities of lipoprotein lipase and hepatic triglyceride lipase. Atherosclerosis 1991;88:175.
7. Homma Y, Ozawa H, Kobayashi T et al. Effects of bezafibrate therapy on subfractions of plasma low-density and high-density lipoprotein and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994;106:191.
8. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyper-lipoproteinemia. Atherosclerosis 1995;114:223.
9. Kuo PT, Hayase K, Kostis JB, Moreyva AE. Use of combined diet and colestipol in long-term (7-7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation 1979;59:199.
10. Brenske JF, Levy RI, Kelsey SF et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984;69:313.
11. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trials results. I, reduction in incidence of coronary heart disease. JAMA 1984;251:351.
12. Witztum JL, Simmons D, Steinberg D et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol and colestipol hydrochloride. Circulation 1989;79:16.
13. Mitsubishi Chemical Corporation. MCI-196, bile acid sequestrant. Drugs Future 1993;18:15.
14. Homma Y, Goto Y, Okajima S et al. Effects of treatment with MCI-196, a new bile acid sequestering resin on plasma lipids and apolipoproteins in type II hyperlipopro-teinemia. Nutr Metab Cardiovasc Dis 1996;6:211.
15. Fisher WR, Zeck LA, Stacpoole PW. Apo B metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm. Arterioscler Thromb 1994;14:501.
16. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18;499.
18. Ranganathan S, Hatori H, Kashyap ML. A rapid flow cytometric assay for low-density lipoprotein receptors in human peripheral blood mononuclear cells. J Lab Clin Med 1995;125:479.
19. Kataoka S, Paichi N, Howard BV. Simplified isoelectric focusing immunoblotting determination of apoprotein E phenotype. Clin Chem 1994;40:11.
20. Noma A, Hato Y, Goto Y. Quantification of serum apolipoprotein A-I, A-II, B,C-II, C-III and E in healthy Japanese by turbidimetric immunoassay; reference values and age-and sex-related differences. Clin Chim Acta 1991;199:147.
21. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1545.
22. Berdery BB, Benham DF, Baldwin HL, Goldleng AP, Nicols AV. Measurement of normative HDL subfraction-cholesterol levels by Gaussian summation analysis of gradient gels. J Lipid Res 1989;30:1085.
23. Nagasaki T, Akanuma, Y. A new colorimetric method for the determination of plasma lecithin: cholesterol acyltransferase activity. Clin Chim Acta 1977;75:372.
24. Albers JJ, Tollefson JH, Chen C-H, Steinmetz A. Isolation and characterization of human lipid transfer proteins. Arteriosclerosis 1984;9:49.
25. Homma Y, Ohshima K, Yamaguchi H, Nakamura H, Araki G, Goto Y. Effects of eicosapentaenoic acid on plasma lipoprotein subfractions and activities of lecithin: cholesterol acyltransferase and lipid transfer protein. Atherosclerosis 1991;91:145.
26. Witztum JL, Young SG, Elan RL, Carew TE, Fisher M. Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I Studies in the guinea pig. J Lipid Res 1985;26:92.
27. Young SG, Witztum JL, Carew TE, Krauss RW, Lindgren FT. Colestipol-induced changes in LDL composition and metabolism. II. Studies in humans. J Lipid Res 1989;30:225.
28. 3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia. Artery 1993;20:1.
29. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986;77:663.
30. Vega GL, Grandy SM. Kinetic heterogeneity of low density lipoproteins in primary hypertriglyceridemia. Arteriosclerosis 1986;6:395.
31. Marzetta CA, Foster DM, Brunzell JD. Conversion of plasma VLDL and IDL precursors into various LDL subpopulations using density gradient ultracentrifugations. J Lipid Res 1990;31:975.
32. Gaw A, Packard CJ, Murray EF et al. Effects of simvastatin on apo B metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13:170-189.
33. De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFM. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy volunteers. Arterioscler Thromb 1991;11:298-306.
34. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189.
35. Shepherd J, Packard CJ, Bicher S, Lawrie V, Morgan HG. Cholestyramine promote receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302:1219.
36. Slater HR, Packard CJ, Bicher S, Shepher J. Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. J Biol Chem 1980;255:10 210.